| Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
| 公開日 |
2017-12-01 |
| タイトル |
|
|
タイトル |
Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
| 著者 |
ANDO, Koichi
TANAKA, Akihiko
YOKOE, Takuya
OHNISHI, Tsukasa
INOUE, Shin
SAGARA, Hironori
|
| 書誌情報 |
The Showa University journal of medical sciences
巻 28,
号 4,
p. 337-347,
発行日 2016-12
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The aim of the present study was to assess the non-inferiority of low-dose benralizumab relative to high-dose benralizumab as a treatment option for uncontrolled eosinophilic asthma through a meta-analysis of efficacy and safety in randomized controlled trials (RCTs). PubMed, the Cochrane Library Database, and Scopus were searched to identify relevant articles. Outcome measures were a change in the Asthma Control Questionnaire-6 (ACQ-6) score and the exacerbation rate. In addition, the meta-analysis assessed the incidence of adverse events, injection site reactions, and pyrexia or influenza-like illness. Two RCTs with two doses of benralizumab (20 and 100mg) and a placebo for the treatment of uncontrolled eosinophilic asthma met the criteria and were included in the present study. Non-inferiority of low-dose (20mg) versus high-dose (100mg) benralizumab was shown for the change in ACQ-6 score, exacerbation rate, and the incidence of adverse events, injection site reactions, and pyrexia or influenza-like illness. Although not significant, the incidence of pyrexia or influenza-like illness was lower in patients treated with low-dose benralizumab. These results suggest that low-dose (20mg) benralizumab is effective for symptom control and reduction of exacerbation rate in uncontrolled eosinophilic asthma, with lower treatment costs. |
| DOI |
|
|
|
関連識別子 |
10.15369/sujms.28.337 |
| 出版者 |
|
|
出版者 |
Showa University Society |
| ISSN |
|
|
収録物識別子 |
0915-6380 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
S28_337.pdf (456.2 kB)
